The response of IDH-wild type recurrent glioblastoma to vascular endothelial growth factor (VEGF) inhibitors can be predicted by the pretreatment MRI contrast enhancing pattern. With predominantly ...

The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain patients with glioblastoma, according to results of a prospective phase 3 trial published ...

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body's ...

Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Study Overview: The FRONTIER study, officially titled ‘A ...

Please provide your email address to receive an email when new articles are posted on . Although the objective response rate exceeded the prespecified control rate, it fell short of achieving the ...

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed ...

The Food and Drug Administration accepted an Investigational New Drug application for MB-109, a novel agent that combines two mechanisms to treat recurrent glioblastoma and high-grade astrocytroma.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...

AUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...